News / Press
Contact
Who We Are
Vision
Leadership
Board of Directors
Scientific Advisors
Strategic Collaborations
Our Focus
Plaque Psoriasis
Atopic Dermatitis
Seborrheic Dermatitis
Scalp Psoriasis
Hand Eczema
Vitiligo
Alopecia Areata
Pipeline
Topical Roflumilast Cream (ARQ-151)
Topical Roflumilast Foam (ARQ-154)
ARQ-252
ARQ-255
Clinical Programs
Clinical Trials
Scientific Publications
Media
Investors
Media
Arcutis Media Resources
Arcutis Media Resources
Roflumilast Foam: Phase 2 Trial for the Treatment of Seborrheic Dermatitis
Seborrheic Dermatitis: Understanding Patient Needs
The Impact of Seborrheic Dermatitis
Arcutis Biopharmaceuticals Corporate Fact Sheet, 4Q 2020
New England Journal of Medicine, Infographic / Backgrounder, July 2020
